Roche and Zealand Pharma reported Phase 2 results for petrelintide, an amylin receptor‑targeting peptide, meeting trial endpoints with tolerability comparable to placebo but producing average weight loss below analyst forecasts. The readout validates target engagement and safety in the amylin axis but raises questions about competitive positioning versus next‑generation GLP‑1/GIP and amylin combos. Partners will need to decide dose optimization, positioning, and next‑step trials against an increasingly crowded anti‑obesity field.